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Retroelements are important evolutionary forces but can be deleterious if left uncontrolled. Members of the
human APOBEC3 family of cytidine deaminases can inhibit a wide range of endogenous, as well as exogenous,
retroelements. These enzymes are structurally organized in one or two domains comprising a zinc-coordinating
motif. APOBEC3G contains two such domains, only the C terminal of which is endowed with editing activity,
while its N-terminal counterpart binds RNA, promotes homo-oligomerization, and is necessary for packaging
into human immunodeficiency virus type 1 (HIV-1) virions. Here, we performed a large-scale mutagenesis-
based analysis of the APOBEC3G N terminus, testing mutants for (i) inhibition of vif-defective HIV-1 infection
and Alu retrotransposition, (ii) RNA binding, and (iii) oligomerization. Furthermore, in the absence of
structural information on this domain, we used homology modeling to examine the positions of functionally
important residues and of residues found to be under positive selection by phylogenetic analyses of primate
APOBEC3G genes. Our results reveal the importance of a predicted RNA binding dimerization interface both
for packaging into HIV-1 virions and inhibition of both HIV-1 infection and Alu transposition. We further
found that the HIV-1-blocking activity of APOBEC3G N-terminal mutants defective for packaging can be
almost entirely rescued if their virion incorporation is forced by fusion with Vpr, indicating that the corre-
sponding region of APOBEC3G plays little role in other aspects of its action against this pathogen. Interest-
ingly, residues forming the APOBEC3G dimer interface are highly conserved, contrasting with the rapid
evolution of two neighboring surface-exposed amino acid patches, one targeted by the Vif protein of primate
lentiviruses and the other of yet-undefined function.
Retroelements have invaded the genomes of all organisms,
from bacteria to primates, in amounts that often greatly exceed
the sum of host protein-coding sequences. As such, they are
essential evolutionary forces, but they must be tightly regulated
to avoid deleterious consequences that would result from their
uncontrolled spreading. The seven members of the human
APOBEC3 family of cytidine deaminases partake in this pro-
cess as innate immunity effectors that inhibit a large panel of
retroelements, from endogenous retrotransposons to exoge-
nous retroviruses (reviewed in references 14 and 22).
APOBEC3 proteins are characterized by the presence of
one or two domains comprising the canonical zinc-coordinat-
ing motif (HXEX24-30PCX2-4C), essential for catalytic activity
(33). APOBEC3G (A3G) contains two such domains, only the
C terminal of which is endowed with editing potential (26, 43),
whereas its N-terminal counterpart is enzymatically inactive
but has RNA binding properties (32, 43). A3G can block the
propagation of Vif-defective (!vif) human immunodeficiency
virus type 1 (HIV-1) (52) but is inactivated by the wild-type
virus through Vif-induced proteasomal degradation (18, 40, 53,
55, 65). In the absence of Vif, the A3G antiviral effect requires
both zinc-coordinating motifs, the N terminal for recruitment
into particles and the C terminal for lethal editing of the viral
DNA. A3G interacts via its N terminus with the nucleocapsid
(NC) moiety of Gag, possibly through an RNA intermediate,
and is thereby recruited at sites of viral assembly at the plasma
membrane (4, 7, 56). Once the virus is in target cells, A3G
interferes with reverse transcription at several steps (24, 25,
41), among which is the C-to-U editing of the nascent minus-
strand viral DNA that critically depends on a functional C-
terminal zinc-coordinating motif (27, 38, 66). It is noteworthy
that the editing activity of A3G is not essential for its blockade
of at least two other retroelements, the hepatitis B virus (58)
and the Alu endogenous retrotransposon (16, 29).
In cells, A3G partakes in high-molecular-mass ribonucleo-
proteic complexes together with close to 100 other proteins
(16, 21, 36). A3G binds single-stranded polynucleotides (32,
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43) and has been found to associate with 7SL, Alu, and hYs
RNAs (16, 62). A3G can also form oligomers (7, 10, 15, 33, 43),
and the small angle of the X-ray scattering profile of these
complexes is compatible with the volume of a homodimer (63).
Mutating the N-terminal zinc-binding motif of A3G abrogates
its RNA binding and self-association potential (43).
The recent structure determination of the A3G C-terminal
domain has shed light on determinants dictating single-
stranded DNA binding and editing (11, 28, 49). In contrast, the
lack of structural data on its N-terminal counterpart, as well as
the absence of enzymatic activity of this domain, have pre-
cluded reaching a similar understanding of the specific roles
played by the zinc-binding motif and other features of this
region of A3G. As a step toward investigating these issues, we
conducted a large-scale mutagenesis/functional study of the
A3G N-terminal module, mapping determinants crucial for
RNA binding; oligomerization; and activity against an exoge-
nous retrovirus, !vif HIV-1, and an endogenous retroelement,
Alu. We then integrated these data in a structural model. Our
results reveal that residues important for the restriction of both
retroelements form a surface predicted to mediate contacts
between two A3G monomers and to form a groove that can
potentially accommodate single-stranded polynucleotides.
Furthermore, the results of phylogenetic analyses indicate that
this region is highly conserved, in contrast with two adjacent
patches of amino acids subjected to positive selection, one
corresponding to the region targeted by Vif, the lentiviral an-
tagonist of A3G, and the other of yet-unknown function.
MATERIALS AND METHODS
Constructs. HIV-1 viruses encoding all but the Vif protein were produced
from the pR9!vif plasmid (60). The plasmids required for the LINE-1-driven
Alu retrotransposition assay were a kind gift from J. V. Moran
(pALU_pA"_neoTET and pJM101_L1.RP_NoNeo) (19, 29). pCMV plasmids
coding for APOBEC proteins fused to a C-terminal hemagglutinin (HA) tag are
described in reference 34. Point mutations were introduced using Quikchange
site-directed mutagenesis (Stratagene). Each mutant was verified by performing
a sequencing reaction. The C-terminal segment 198 to 384 of A3G was amplified
from pCMV-A3G-HA by PCR using primers A3G198-384_F, 5# GCGTATCG
ATAAGCTTGGCCAAGGATGGATCCACCCACATTCAC 3#, and 009, 5#
GCACTGGAGTGGCAACTTCC 3#, and introduced back into pCMV-
A3G-HA with HindIII and XbaI to replace the wild-type protein. The plasmid
coding for C-terminally myc-tagged A3G under the cytomegalovirus promoter
was obtained by D. Kabat through the AIDS Research and Reference Reagent
Program (pCDNA3.1.A3G-myc-His). The Vpr construct with residues 1 to 14
deleted (Vpr14-88) was cloned from the wild-type HIV-1 plasmid pR9 (60) by
PCR using primers Vpr_BF, 5# CCGGGGGGAAGCTTGGCCACCATGCCATA
CAATGAATGGACA 3#, and Vpr_ER-pcs, 5# CCGGGGGGAAGCTTTTCCA
CCTACGATCGGATAATTCTGGCTTACTCTCCTCTGTCGAGTAAC 3#,
and a proofreading DNA polymerase (PfuTurbo, Stratagene). The Vpr_ER-pcs
primer contains the HIV protease-dependent cleavage site SQNYPIV. The PCR
fragment obtained was next introduced into the HindIII site of pCMV-A3G-HA
to obtain plasmid pCMV-Vpr14-88-A3G-HA. The plasmid coding for Vif C133S
is described in reference 34 (pRRLsin.cPPT.PGK.GFP-2A-Vif-myc).
Cell culture and transfection. HEK293T and CD4", HIV-1 long terminal
repeat–LacZ-containing, HeLa-derived P4.2 cells (9) were regularly passaged in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum, 2
mM glutamine, and antibiotics (100 U/ml penicillin and 100 mg/ml streptomy-
cin), while HeLa HA cells were passaged in minimum essential medium supple-
mented with nonessential amino acids (Gibco) in addition to 10% fetal calf
serum, antibiotics, and 2 mM glutamine. HEK293T cells were transfected by
using Fugene 6 (Roche) or Lipofectamine 2000 (Invitrogen), following the man-
ufacturer’s instructions. HeLa HA cells were transfected with Fugene 6 using a
previously described protocol (29).
Single-round HIV-1 infectivity assay. Viruses were produced in duplicates by
transfection of HEK293T cells seeded in six-well plates, using the pR9!vif
plasmid, in the presence or of or without APOBEC proteins. To determine the
activity levels of the mutants independently of their expression levels (see Fig.
2C), we produced !vif HIV-1 viruses in the presence of wild-type A3G at three
or four different doses and compared the restriction activity levels of the mutants
to that of the corresponding dose of the wild type. At 12 h posttransfection, the
medium was changed, and it was collected 24 h later. Cell-free virions were
prepared by filtration through a 0.45-$M-pore-size nitrocellulose membrane
(Spin-X; Corning) and concentrated in a microcentrifuge for 1.5 h at 13,000 rpm
at 4°C. The pellet was resuspended in 20 $l of phosphate-buffered saline, and the
amount of physical particles was monitored by reverse transcriptase activity assay
(1). The infectious titer was determined by duplicate infections on the P4.2
indicator cell line (39). The specific titer was calculated by dividing the infectious
titer by the amount of physical particles as determined by reverse transcriptase
activity. The expression level of APOBEC proteins was evaluated by Western
blot analysis of 2 $g of cell extract collected at the time of virion harvesting. To
evaluate the amount of APOBEC protein inside viral particles, an equivalent of
1.5 % 106 cpm of virions was run on a sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) gel. APOBEC proteins were detected with a
mouse HA-specific, peroxidase-conjugated 3F10 monoclonal antibody (Roche).
The viral capsid was detected by using mouse p24-specific antibody (B. Chesebro
and H. Chen through the AIDS Research and Reference Reagent Program).
Alu retrotransposition assay. The LINE-1-driven Alu retrotransposition as-
say was performed as previously described (29). Briefly, 3 % 105 to 5 % 105
HeLa HA cells were seeded into T75 flasks and transfected 15 h later with
pALU_pA"_neoTET, pJM101_L1.RP_NoNeo, and pCMV5 or an APOBEC-
encoding plasmid. Three days posttransfection, the cells were selected with G418
at 2 mg/ml for 2 days and then at 0.5 mg/ml for 4 to 5 more days. Colonies were
then fixed with ethanol and stained with crystal violet and counted, and the
counts averaged from duplicates. The expression levels of APOBEC proteins
were evaluated by Western blot analysis of lysate from cells transfected in
parallel and collected at the time of selection. Evaluation of the expression-
independent activity of the mutants was performed by transfecting wild-type
A3G at three different doses and comparing the activity levels of the mutants to
that of the corresponding dose of the wild type.
Immunoprecipitation. Transfected HEK293T cells were lysed in radioimmu-
noprecipitation assay buffer supplemented with antiprotease cocktail set I (Cal-
biochem) and 100 U/ml of RNase inhibitor (RNAseIN; Promega). After a short
spin to remove cell debris, a 50- to 100-$g amount of cell lysate was adjusted to
500 $l with lysis buffer. Ten microliters was retrieved and loaded on a SDS-
PAGE gel, and 20 $l was used for reverse transcription-PCR (RT-PCR). Forty
microliters of anti-HA affinity matrix (Roche) was added to the rest of the mix,
which was swirled for 2 to 3 h at 4°C and then extensively washed using radio-
immunoprecipitation assay buffer supplemented with NaCl at up to 500 mM.
After the last wash, half of the beads were incubated in &-mercaptoethanol and
SDS-containing buffer for 3 min at 95°C before being run on a SDS-PAGE gel.
RNA was extracted from the other half and analyzed by RT-PCR. For myc-
tagged A3G, immunoprecipitations were performed similarly, using anti-c-Myc
affinity matrix (Santa Cruz), and the protein was detected by Western blotting
with a mouse anti-c-Myc antibody (Roche).
RT-PCR analysis. RNA was extracted using an RNeasy mini kit (Qiagen).
After DNase treatment (Sigma), RNA was reverse transcribed using random
hexamers and Superscript III reverse transcriptase as recommended by the
manufacturer (Invitrogen). For each sample, a control reaction lacking the en-
zyme was included to check for contaminating DNA. We amplified the resulting
cDNAs by PCR using GoTaq green master mix (Promega) and specific primers
for 7SL (7SL_BF2, 5# TCCGCACTAAGTTCGGCATC 3#, and 7SL_ER2, 5#
AGTGGCTATTCACAGGCGCG 3#), hY1 (hY1_F2, 5# CTGGTCCGAAGGT
AGTGAG 3#, and hY1_R2, 5# CTAGTCAAGTGCAGTAGTG 3#), hY3
(hY3_F2, 5# GCTGGTCCGAGTGCAGTGGTGTTTAC 3#, and hY3_R2, 5#
AGGCTAGTCAAGTGAAGCAGTG 3#), and Alu (AluWBF, 5# TCACGCCT
GTAATCCCAGCA 3#, and AluR2, 5#GATCTCGGCTCACTGCAAG 3#). The
linearity of the PCR was verified by parallel amplification of serially diluted
human genomic DNA.
Structural model. The N-terminal domain of the ABC3G_HUMAN sequence
(residues 12 to 194; UniProtKB [59] code Q9HC16) was defined as the target
sequence, while the recently resolved human A3G C-terminal domain (28) (PDB
[3] ID 3E1U) served as a template. The two A3G domains show a good sequence
identity (36%). Sequence alignment was done with the align2d function of the
MODELLER program (50), as well as with the CLUSTALW (13) and T-
COFFEE (44) algorithms, and subsequently modified based on structural align-
ments with CHIMERA (47).
Homology models were built with the MODELLER program (50); 1,000
models were calculated and scored with the MODELLER objective function and
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the ANOLEA energy (42) using the default 5-residue-window averaging.
ANOLEA estimates the folding free energy of each amino acid in a three-dimen-
sional structure. The model with a MODELLER objective function of less than
1,100 and the best ANOLEA energy for the nonloop regions was chosen for
further refinement. Residues 140 to 146 were treated with the MODELLER
loop refinement routine because of their poor alignment with the template
structure. Again, 1,000 models were calculated, and the best conformation ac-
cording to its ANOLEA score was used in the refined A3G monomer model. A
zinc ion was added to the pseudoactive site of the model before it was energy
minimized with the CHARMM program (6) and the CHARMM22 all-atom
force field (37). The minimization consisted of 100 steps of steepest descent. A
harmonic restraint of 5 kcal/mol/Å2 toward their initial position was imposed on
all heavy atoms except for the zinc site residues His65, Glu67, Cys97, and Cys100,
which were restrained to display the same distances to the zinc ion as in the X-ray
structure. Two copies of the final N-terminal model were structurally aligned to
chains A and C of the APOBEC2 (A2) tetramer (48) (PDB ID 2NYT) in order
to create a putative A3G head-to-head dimer structure. The side-chain confor-
mations of residues 27 and 124 to 127 at the dimerization interface were reas-
signed using SCWRL3 (8) and minimized again with CHARMM in order to
remove clashes. The FoldX program (23) was used to perform an in silico alanine
scan by mutating each residue to an alanine and estimating the change of folding
energy. Molecular visualization and structural alignments were done using
CHIMERA (47).
RESULTS
Common determinants on the A3G N-terminal domain are
required for the inhibition of !vif HIV-1 and Alu. To initiate a
structure-function study of the human A3G N-terminal do-
main, we first individually mutated 55 residues in this region
(Fig. 1A) (67), concentrating on positions that are highly con-
served among primate orthologues or subjected to positive
selection during primate evolution (46, 51) and opting for
conservative amino acid substitutions in most cases (5). Thirty-
six of the resulting mutants exhibited wild-type steady-state
levels of expression, while 19 appeared less stable (Fig. 1B).
We then tested these derivatives for their efficiency at blocking
!vif HIV-1 infection and Alu retrotransposition in single-
round assays (Fig. 2). Although the magnitudes of the block-
ades obtained with wild-type A3G differed between the two
systems, in both cases it was dose dependent, with the inactive
A2 serving each time as a negative control (Fig. 2A). Remark-
ably, all mutants exhibited parallel phenotypes for both classes
of retroelements: of the well-expressed mutants, six (S28A,
W94L, Y124A, Y125A, F126L, and W127L) exhibited marked
decreases in !vif HIV-1 and Alu restriction, whereas one, the
D130K mutant, had instead a reproducible increase in inhibi-
tory potency (Fig. 2B). The W127A mutant, slightly more sta-
ble than the W127L mutant described previously (31), was also
defective (not illustrated). In contrast, mutations at several
positions subjected to positive selection during primate evolu-
tion (Tyr13, Arg29, Glu85, Lys99, Arg102, and Asp128) did not
affect activity against !vif HIV-1 or Alu (data not shown). The
activity levels of the 19 less stable mutants were normalized for
the expression levels. Eleven of them (F21L, R30E, E85Q,
P96L, L108A, L116A, L123A, L138A, M152A, C160S, and
F164L) then appeared as active as the wild type against both
!vif HIV-1 and Alu (not illustrated), while eight, including
derivatives carrying changes in zinc-coordinating residues
(H65R, E67Q, C97S, and C100S), were defective (Fig. 2C).
This result highlights the importance of an intact N-terminal
zinc-coordinating motif for inhibiting both retroelements, con-
tradicting a previous report that this motif is dispensable for
Alu restriction (16). We also tested two C-terminal domain
mutants, one at a position homologous to the N-terminal
Trp94 (W285L) and the other with a change at a zinc-binding
position (C288S). These two residues have been shown to
contribute to the catalytic activity of recombinant C-terminal
domain A3G (11, 12). Both mutants were defective for !vif
HIV-1 restriction but fully competent for Alu inhibition (Fig.
2D), consistent with the previously noted importance of editing
for blocking the former but not the latter (16, 29, 38).
FIG. 1. Large-scale mutagenesis of A3G N-terminal domain residues and effects on steady-state levels of the proteins. (A) Amino acid
sequence of human A3G positions 1 to 194, with mutated residues analyzed for restriction activity marked with an asterisk. (B) Steady-state levels
of wild-type (WT) A3G in HEK293T cells transiently transfected with threefold dilutions of the wild type and the highest dose (1 $g) of mutant
plasmid DNA, analyzed by Western blotting using HA-specific antibodies. Mutants with steady-state levels lower by threefold or more than that
of the wild type are highlighted in bold. anti-Tub, antitubulin.
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Functionally defective N-terminal A3G mutants are also
impaired for RNA binding and oligomerization. Interaction
with RNA seems to govern two properties of A3G, namely,
binding to the HIV-1 NC, which leads to recruitment into
nascent particles, a prerequisite for viral inactivation, and oli-
gomerization (4, 15, 56). Furthermore, an intact N-terminal
zinc-coordinating motif is required for the self-association of
A3G, as well as RNA binding (43). Therefore, we probed the
RNA binding ability of A3G N-terminal mutants by RT-PCR
analysis of immunoprecipitates recovered from transiently
transfected HEK293T cells (Fig. 3). Contrary to the results for
A2, wild-type A3G was found to associate with hY1, hY3, 7SL,
and Alu RNAs, as previously described (16, 62). In contrast,
functionally defective N-terminal mutants had, to various de-
grees, a decreased affinity for one or more of these RNAs.
Although the background level was relatively high for Alu (Fig.
3, lane marked “no RT”), interaction with this RNA was re-
duced to negligible levels for the two most inactive mutants,
the W94L and W127A mutants. The D130K and W285L mu-
tants did not show a significant change of affinity for any RNA
tested.
To evaluate the oligomerization potential of the A3G mu-
tants, we expressed them as HA-tagged derivatives together
with myc-tagged wild-type A3G and performed HA- and myc-
specific Western blot analyses of antimyc-mediated immuno-
precipitations (Fig. 4). While wild-type HA-tagged A3G effi-
ciently coimmunoprecipitated with its myc-tagged counterparts,
N-terminal mutants were impaired for oligomerization to de-
grees largely corresponding to their RNA binding and antiviral
activity defects (Fig. 4A, left). In contrast, three mutations in
the C-terminal domain of A3G (W285L, C288S, and Y315A),
in spite of being at positions homologous to those in three
N-terminal oligomerization-defective mutants (W94L, C97S,
and Y124A) (45), had no impact on A3G self-association (Fig.
4A, right). Neither APOBEC3A (A3A) nor a version of A3G
with an N-terminal deletion (A3G198-384) (12) could bind
wild-type A3G (Fig. 4B). Interestingly, most of the A3G oli-
gomerization determinants identified in this work have aro-
matic groups (Trp94, Tyr124, Tyr125, Phe126, and Trp127),
most of which do not have counterparts in A3A and in the
C-terminal domain of A3G. Unfortunately, A3G derivatives
lacking the C-terminal domain were unstable and could not be
tested for RNA binding or self-association.
Individual mutations of two aspartates to lysine at positions
128 and 130 of A3G impair recognition by HIV-1 Vif (31, 39).
Owing to the close proximity of these residues to the patch at
residues 124 to 127 that is involved in oligomerization, we
investigated whether Vif could prevent A3G complex forma-
tion. For this, we performed the myc-/HA-tagged A3G coim-
munoprecipitations in the presence or absence of HIV-1 Vif
C133S, which binds A3G but fails to trigger its proteasomal
degradation (35). As reported previously (35), Vif C133S did
FIG. 2. Functional analysis of wild-type (black bars) and mutant A3Gs against !vif HIV-1 and Alu through single-round assays. (A) Dose-
dependent inhibition of !vif HIV-1 and Alu replication, with A2 serving as negative control, as described in Materials and Methods. Transfection
with the Alu reporter in the absence of a LINE-1 helper plasmid (Alu w/o L1; w/o, without) was performed to control the LINE-1 dependency of
neomycin resistance. (B to D) Relative restriction activities of stably expressed N-terminal domain mutants (B) and of N-terminal domain mutants
with low steady-state levels before (dark gray) or after (light gray) normalization for expression levels (C), all expressed as a percentage of the
wild-type activity. (D) Impact of C-terminal domain mutants on !vif HIV-1 and Alu replication. Means and standard errors are representative of
the results for independent duplicates from a single experiment (A and D) or from one to three different experiments (B and C). pCMV5, empty
vector; WT, wild type; IU, infectious units; cpm, counts per minute; N.D., not done.
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not affect the antiviral potency of A3G (data not shown). In
line with this result, it did not interfere with A3G oligomer-
ization, in spite of associating with the cytidine deaminase (Fig.
4C). Of note, the mutants D128K and D130K that do not bind
Vif had full oligomerization and RNA binding abilities (Fig. 3
and 4A), and the oligomerization-defective A3G W94L and
W127A mutants were efficiently degraded by wild-type Vif (data
not shown) (31). Altogether, these data indicate that distinct
A3G domains dictate oligomerization and recognition by
HIV-1 Vif.
Functional rescue of inactive A3G N-terminal domain mu-
tants by forced packaging into HIV-1 virions. The incorpora-
tion of A3G into assembling HIV-1 particles is essential for its
antiviral activity against this pathogen (43). As a remarkable
correlate, the functional defects of well-expressed A3G N-
terminal domain mutants with impaired RNA binding and
antiviral activities were inversely proportional to their packag-
ing efficiency (Fig. 5A), in agreement with the RNA-dependent
association of A3G to the HIV-1 NC (4, 56). This is notably
exemplified by the S28A and S28E mutants, whose impact on
!vif HIV-1 infectivity closely paralleled their packaging effi-
ciencies. In contrast, the C-terminal W285L mutant was effi-
ciently encapsidated in spite of its restriction defect. To further
probe the contribution of the packaging defect of A3G N-
terminal mutants to their functional impairment, we forced
their encapsidation by fusion with a fragment of the HIV-1 Vpr
protein that was sufficient for recruitment into viral particles
but devoid of cytotoxicity (amino acids 14 to 88) (2). A peptide
linker that is sensitive to the viral protease was placed between
the two parts of the resulting fusion proteins, allowing the
release of the A3G moiety following virion maturation to avoid
subsequent influence of Vpr on the A3G activity. Vpr-medi-
ated particle incorporation significantly rescued the antiviral
phenotype of the packaging-defective A3G mutants (Fig. 5B).
Although the activities of the least-defective mutants were not
fully restored, the antiviral effects of the S28E, W94L, and
W127A mutants increased approximately 10 times in this con-
text. This indicates that N-terminal residues that are essential
for A3G packaging do not subsequently play a major role in
HIV-1 inhibition. In contrast, the W285L catalytic mutant re-
mained inactive even when fused to Vpr.
Modeling a head-to-head dimer of A3G. A clear interpreta-
tion of our functional and biochemical data is complicated by
the absence of any structural information on the N-terminal
domain of A3G, due at least in part to the insolubility of the
full-length protein at high concentration (11). It would be
particularly interesting to determine whether determinants of
restriction are part of a single domain or are dispersed in
different areas. Taking advantage of the recently published
crystal structure of the A3G C-terminal domain (residues 197
to 384) (28) and of the good sequence identity between the two
domains (36%), we modeled the structure of the N-terminal
FIG. 3. Small cellular RNA binding abilities of A3G N-terminal mutants. Extracts of HEK293T cells transiently transfected with plasmids
expressing HA-tagged forms of A2 and wild-type and mutant A3G were either first immunoprecipitated (IP) with HA-specific antibodies (IP:
anti-HA) or directly analyzed (Lysate) by Western blotting (for HA) or semiquantitative RT-PCR with primers specific for indicated small RNAs.
Right panel shows results for 10-fold dilutions of human genomic DNA. “No RT” indicates control sample run in the absence of reverse
transcriptase enzyme. WB, Western blotting.
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domain (residues 13 to 194) using the MODELLER program
(50). As the sequence identity between these structures is sig-
nificantly higher than that with A2 (27%), the model presented
herein may be considered more reliable than earlier A3G
models based solely on A2 (30, 67).
Our model is shown in detail in Fig. 6. It has a good
ANOLEA score profile (data not shown), with a pattern com-
parable to that of the X-ray structure of the C-terminal do-
main, indicating good reliability of the predicted structure.
Like the C-terminal domain, the N-terminal region of A3G
forms a central anti-parallel &-sheet surrounded by '-helices.
The positions of the loops delimited by residues 22 to 34 and
56 to 64 differ significantly and the regions containing residues
123 to 134 and 140 to 146 differ to a lesser extent from models
based on A2. In our model, the N-terminal residues found to
affect the expression of A3G upon mutation (Fig. 1B) are
either linked to the zinc ion (His65, Glu67, Cys97, and Cys100)
or have an important structural function (Fig. 6A), as sug-
gested by an in silico alanine scan of the model (see Table S1
in the supplemental material). Out of those mutants, the ones
that are defective regardless of their expression level (Fig. 2C)
are modified at positions involved in zinc binding (His65,
Glu67, Cys97, and Cys100) or seem to play a prominent role in
stabilizing the structure of the protein (Phe70, Tyr91, and
Ile118) (Fig. 6A; also see Table S1 in the supplemental mate-
rial). Although Arg122 was not predicted to influence the
overall structure of A3G, its high degree of conservation
among cytidine deaminases, including A2, correlates with its
important functional role. Since zinc often stabilizes protein
domains (57), the disruption of this motif in the A3G N ter-
minus might alter function indirectly, by altering local confor-
mation. For A2, a single-domain cytidine deaminase, two
monomers assemble in a long anti-parallel &-sheet with one
zinc-coordinating domain at each extremity (48). Two of those
dimers interact to form a linear tetramer. Since most of the
residues important for A3G self-association resided in regions
homologous to the ones mediating A2 tetramer formation and
since various experiments have suggested that A3G could
form, among different heterogeneous complexes, a homodimer
(7, 10, 15, 33, 43, 63), we built a structural model of an A3G
head-to-head dimer by structural alignment of two A3G N-
terminal domains to two A2 monomers (Fig. 6B). In this
model, the residues found to be important for A3G function-
ality (Ser28, Trp94, Tyr124, Tyr125, Phe126, and Trp127) par-
take in stabilizing the dimer, notably, by forming numerous
(-( interactions between the five aromatic residues and their
cognate copies from the other monomer (Fig. 6C). Trp127
makes extensive contacts with Trp94 and Tyr124 of the other
monomer. In agreement, the W94L and W127A mutants were
the two mutants with the weakest binding affinity for wild-type
A3G (Fig. 5A). Although they do not make direct contacts with
Ser28 on the other monomer, Asp128 and -130 are in close
proximity to it, an observation that parallels the observation of
a reduced capacity of S28E, in comparison to that of S28A, to
oligomerize with wild-type A3G (Fig. 5A). Two additional
residues participating in intersubunit contacts on A2 (48) are
FIG. 4. A3G homodimerization is affected by N-terminal domain mutations but not by the presence of Vif C133S. (A) Indicated HA-tagged
wild-type A3G and mutants were transiently coexpressed in HEK293T cells along with myc-tagged wild-type A3G ("). Cell lysate (Lysate) and
immunoprecipitated material (IP: antimyc) were loaded onto SDS-PAGE gels, followed by Western blot analysis using HA- and myc-specific
antibodies. A3G-HA alone served as control for nonspecific binding (first lane). (B) HA-tagged A3A, A3G, and A3G198-384 were cotransfected
with A3G-myc (") in HEK293T cells, and lysates were either directly loaded onto SDS-PAGE gels (Lysate) or used for immunoprecipitation using
anti-HA-coated beads (IP: anti-HA). A3G-myc alone served as control for nonspecific binding. (C) Cells transiently expressing wild-type myc- and
HA-tagged A3G in the presence or absence of Vif C133S were lysed and used for immunoprecipitation with anti-HA-coated beads. Vif C133S and
A3G-myc alone served as controls for nonspecific binding. ", present.
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present on a helix corresponding to the most C-terminal helix
in our model. Nine mutations in this helix (F157L, N176D,
K180A, Y181A, I183A, L184A, I187A, E191Q, and I192A) did
not affect A3G self-association in coimmunoprecipitation ex-
periments (data not shown). Although this helix is close to the
putative dimer interface, it displays less-extensive interactions
with the other monomer than the loop containing residues 124
to 127 or the corresponding helix in the A2 tetramer, in agree-
ment with the results of our mutational analysis.
The dimer interface forms a groove with a width of approx-
imately 10 Å (Fig. 6D, side view), compatible with the diameter
of single-stranded but not double-stranded polynucleotidic
chains, in agreement with in vitro data (64). The aromatic
residues Trp94 and Tyr124 to Trp127 located at the bottom
could interact with the nucleotide bases. The corners of the
groove are delimited by two negatively charged residues, Asp128
and Asp130, which do not have extensive interactions with the
other monomer, in agreement with our coimmunoprecipita-
tion data (Fig. 5A). Primate A3Gs have an unusually high rate
of residues under positive selection, characteristic of rapid
evolution (46, 51). Mapping these residues onto the model
reveals that the large majority occur on one side of the dimeric
protein, leaving the other side with only a few such residues
(Fig. 6D, top view and bottom view, respectively). At the dimer
interface, a patch of amino acids subjected to positive selection
is centered on the Vif-binding site, previously demonstrated to
comprise residues 128 to 130 (Fig. 6D, side view) (31, 67).
Alignment of Old World monkey and hominid A3Gs shows
that conserved residues overlap with secondary structure ele-
ments, further supporting the validity of our model (Fig. 7). In
the loop domains, the three largest clusters of conserved res-
idues encompass one or more of the six amino acids identified
as important for restriction (Ser28, Trp94, Tyr124, Tyr125,
Phe126, and Trp127).
DISCUSSION
In the present work, we combined functional analyses and
structural modeling to delineate a structural region of the A3G
N terminus that is involved in mediating oligomerization and
RNA binding and is essential for A3G packaging into HIV-1
virions, inhibition of !vif HIV-1 infectivity, and blockade of
Alu retrotransposition. This structural region notably encom-
passes a series of aromatic residues, Trp94, Tyr124, Tyr125,
Phe126, and Trp127, that are predicted to mediate intersub-
unit contacts through a series of (-( interactions, as is often
found at protein-protein interfaces (17). The dimer interface is
further characterized by the formation of a putative groove
that has the width and electrostatic potential to bind single-
stranded but not double-stranded polynucleotides. Although
our data do not formally demonstrate the presence of a dimer
rather than a higher-order structure, recent evidence indicates
that the major form of oligomer detected in experimental
settings comparable to ours is a dimer (30). In that report,
Huthoff et al. similarly proposed an A3G head-to-head dimer
model, mainly based on analysis of mutants with the two N-
terminal mutations Y124A and W127A and homology with the
structure of A2. The two models show striking similarities,
notably revealing the importance of residues 124 to 127 in
establishing intermonomeric contacts. However, interesting
differences emerge between the two models, probably stem-
ming from the use here of the now-available structure of the
FIG. 5. Encapsidation and antiviral activities of packaging-defective A3G N-terminal domain mutants are rescued by fusion with Vpr14-88.
Top, relative infectivity levels of !vif HIV-1 exposed or not to wild-type or mutant A3G. Infectivity of viruses produced in the absence of A3G
was given the arbitrary value of 100. Values represent means and standard errors of the results from independent duplicates. Bottom, Western blot
analyses of cellular and viral extracts using HA-, tubulin- (anti-Tub), or p24-specific antibodies. (A) Results with native A3G. (B) Results with
Vpr14-88-A3G fusion proteins.
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more closely related A3G C terminus as a template, while that
of the more distant A2 was utilized by Huthoff et al. For
instance, their study did not predict the putative RNA-accom-
modating groove created at the dimer interface, due to a dif-
ferent positioning of the loop containing residues 22 to 34
which buried the zinc-coordinating motif and placed Ser28 far
from the other monomer. Also, a more twisted dimer posi-
tioned Asp128 at the dimerization interface, resulting in con-
tacts with Arg122 of the other monomer, a possibility difficult
to reconcile with the absence of both any oligomerization phe-
notype of the D128K mutant and the accessibility of this res-
idue to Vif (Fig. 4A). Finally, Huthoff et al. found that posi-
FIG. 6. Homology dimer model of A3G. (A) A3G N-terminal domain model based on homology with the crystal structure of the A3G C
terminus. Residues affecting protein steady-state level when mutated are indicated as follows. Magenta, mutants are functionally defective even
after normalization for expression levels (Fig. 2C); light blue, mutants are as active as the wild type after normalization for expression levels (Phe21,
Glu85, Pro96, Leu108, Leu116, Leu123, Leu138, Met152, Cys160, and Phe164). (B and C) Nitrogen, oxygen, sulfur, and zinc atoms are depicted
in blue, red, yellow, and magenta, respectively. (B) Top view of the dimer model, showing two N-terminal domains of A3G (one green and the
other blue) in a head-to-head complex, as modeled from the A2 tetramer structure. Zinc-binding residues (His65, Glu67, Cys97, and Cys100) are
shown in gray. (C) The predicted dimer interface in detail, with residues important for A3G oligomerization and !vif/Alu restriction shown in
orange. Intersubunit contacts of the aromatic side chains allow the formation of energetically favorable (-( interactions. (D) Space-filling
visualization of A3G dimer. As in panel C, the surface of the residues important for oligomerization is depicted in orange. Yellow surfaces
correspond to the residues found to be under positive selection in primate A3Gs. The side view evidences the 10-Å groove formed by the two
monomers at the dimer interface, as well as the residues under positive selection that are close to the Vif-binding site comprising residues 128 to
130. Thr32 and Asp130 (labeled in white) are two conserved residues that both influence recognition by HIV-1 Vif.
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tively charged amino acids located at the edge of the dimer
interface (Arg24, Arg30, and Arg136) might engage in stabi-
lizing interactions with RNA. However, Arg24 (54) and Arg30
(Fig. 1B; also see Table S1 in the supplemental material) were
both found to contribute to protein stability, suggesting that
these residues influence RNA binding only indirectly. In addi-
tion, we observed that charge-inverting mutations at four other
positions on the same interface (Arg29, Lys63, Lys99, and
Arg102) did not reduce A3G restriction activity or RNA bind-
ing (not illustrated).
Our functional analyses confirm that the C-terminal catalytic
site of A3G promotes !vif HIV-1 but not Alu inhibition. In
contrast, they indicate that A3G requires an intact dimeriza-
tion domain to act against both classes of retroelements. In the
case of HIV-1, however, the implicated residues seem neces-
sary mainly for gaining access to budding viral particles. In-
deed, the defective phenotype of all derivatives impaired for
packaging due to mutations at these positions could be rescued
by forcing their incorporation into virions by fusion with Vpr
(Fig. 5B). Thus, the N-terminal module of A3G does not ap-
pear to play a major role in other aspects of the antiviral effect
of the cytidine deaminase on HIV-1. In contrast, in the absence
of a clearer understanding of how A3G blocks Alu retrotrans-
position, the role of the N-terminal domain in this process can
only remain speculative. Some degree of correlation between
Alu RNA binding ability and the Alu inhibition potential of the
mutants studied here (Fig. 3) suggests a model whereby A3G
blocks retrotransposition of this element by sequestering its
RNA away from the LINE trans-acting proteins. However, this
simple model is not supported by data obtained with A3A,
since in the experimental system described here, this cytidine
deaminase exhibited far greater levels of anti-Alu activity than
A3G but no obvious affinity for its RNA, at least based on the
results of RT-PCR analysis of A3A-specific immunoprecipi-
tates (not illustrated).
The potential RNA-accommodating groove formed by the
dimer interface (Fig. 6D) is consistent with the RNase sensi-
tivity of A3G oligomers (45). Furthermore, the fact that mu-
tations abrogating dimerization and perturbing association
with small cellular RNAs also prevented packaging into HIV-1
virions indicates that these three events are linked. The RNase
sensitivity of the A3G-HIV-1 NC interaction was previously
interpreted as indicating that an RNA intermediate is involved
in linking the two partners (4, 56). Alternatively, it could be
that NC does not recognize A3G as a monomer but as a dimer,
the stabilization of which is RNA dependent. However, the
apparent promiscuity of A3G packaging, which can be re-
cruited into HIV-1 virions via either the cognate retroviral NC
or its severe acute respiratory syndrome coronavirus homo-
logue (61), makes a protein-protein-only interaction less likely,
unless it is primarily structural motifs rather than specific
amino acid sequences that are at play.
Several studies have pointed to the role of Asp128 and
Asp130 in binding Vif (31, 39). A recent report indicated that
Thr32 might be involved as well (54). On the A3G monomer,
Asp128/Asp130 and Thr32 are located on opposite sides of
the dimerization-mediating aromatic stretch. However, in
our dimer model, Thr32 is situated close to Asp128 of the
adjacent monomer (Fig. 6D, side view). Together with the
results of coimmunoprecipitation studies indicating that Vif
does not prevent A3G oligomerization (Fig. 4C), this strongly
suggests that Vif can recognize a cytidine deaminase dimer.
From a therapeutic perspective, since Vif binding and A3G
function involve distinct regions, possible side effects of a Vif-
targeting drug on A3G activity may be limited.
Considering that A3G dimerization and RNA binding are
FIG. 7. Alignment of hominid and Old World monkey A3Gs. The alignment shows high conservation in predicted secondary structures
deduced from the model (orange and green rectangles), as well as in loops containing the residues involved in restriction activity (orange-dashed
boxes), as seen by the results in Fig. 2B. Alignment was performed using MUSCLE (20). Dark blue,)80% homology; blue,)60% homology; light
blue,)40% homology; white,*40% homology; PANTR, Pan troglodytes; PANPA, Pan paniscus;GORGO,Gorilla gorilla; PONPY, Pongo pygmaeus;
PAPAN, Papio anubis; MACMU, Macaca mulatta; MACNE, Macaca nemestrina; MACNG, Macaca nigra; MACFA, Macaca fascicularis; ERYPA,
Erythrocebus patas; CERAE, Cercopithecus aethiops.
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important for inhibiting retroelements as distant as HIV-1 and
Alu, it is not surprising that the residues involved in this pro-
cess are highly conserved (Fig. 7). Notably, the subjection of
residues located at the corner of the dimer interface to positive
selection (Fig. 6D, side view) (46, 51) is consistent with their
recognition by the A3G antagonist Vif (31, 67). In contrast,
there is no obvious explanation for the finding that another
group of residues lined up on one side of the protein (Fig. 6D,
top view versus bottom view) similarly underwent rapid evolu-
tion. While it is tempting to postulate that these positions
might be important for target recognition, the normal levels of
activity of the corresponding mutants against both HIV-1 and
Alu suggest that these elements at least were not responsible
for the selective pressure exerted at these positions, leaving the
nature of the underlying evolutionary forces undefined.
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